� OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated EDC solutions for clinical trials, today announced that the party is providing EDC software and services for a Phase II trial in BRCA 1/2 and HNPCC patients sponsored by the Tucson Arizona based biotech, Systems Medicine LLC (SML). SML initially began its relationship with OmniComm through OmniComm's CRO Preferred Program� and then selected OmniComm as its EDC marketer of selection for their Phase II study.
"Our initial experience in working with OmniComm was very favorable and as a result we chose to use them in our next run. We were impressed with their responsiveness and professionalism throughout the entire negotiation and subject build process," said Patrick Shannon, Ph.D., Senior Director Project Management for Systems Medicine LLC.
Systems Medicine, LLC (SML) develops oncology products by integrating prognostic cellular pharmacogenomics ("genomics") with world-class clinical and regulative expertise. This allows SML to germinate patient-selective therapies by defining the context of use of exposure of cancer and treating only those patients to the highest degree likely to respond to specific drugs or dose combinations. For more
